Trexquant Investment LP Sells 168,085 Shares of Pediatrix Medical Group, Inc. $MD

Key Points

• Trexquant Investment LP reduced its stake in Pediatrix Medical Group by 39.0%, owning approximately 263,145 shares valued at $3.81 million after selling 168,085 shares in Q1.
• Pediatrix Medical Group reported earnings per share (EPS) of $0.53, exceeding analysts' expectations of $0.42, with quarterly revenue at $468.84 million.
• Currently, Pediatrix Medical Group's stock has a Moderate Buy rating with an average target price of $16.75 according to sell-side analysts.

Trexquant Investment LP cut its position in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 39.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 263,145 shares of the company's stock after selling 168,085 shares during the period. Trexquant Investment LP owned about 0.31% of Pediatrix Medical Group worth $3,813,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of MD. Boston Partners grew its stake in Pediatrix Medical Group by 1.3% during the first quarter. Boston Partners now owns 1,981,889 shares of the company's stock valued at $27,990,000 after acquiring an additional 25,536 shares in the last quarter. Northern Trust Corp grew its stake in Pediatrix Medical Group by 18.0% during the fourth quarter. Northern Trust Corp now owns 966,347 shares of the company's stock valued at $12,678,000 after acquiring an additional 147,522 shares in the last quarter. Invesco Ltd. grew its stake in Pediatrix Medical Group by 9.3% during the first quarter. Invesco Ltd. now owns 863,269 shares of the company's stock valued at $12,509,000 after acquiring an additional 73,157 shares in the last quarter. Principal Financial Group Inc. grew its stake in Pediatrix Medical Group by 6.2% during the first quarter. Principal Financial Group Inc. now owns 586,190 shares of the company's stock valued at $8,494,000 after acquiring an additional 34,266 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Pediatrix Medical Group during the first quarter valued at $8,024,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. UBS Group raised their target price on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the company a "neutral" rating in a research note on Thursday, August 14th. Macquarie raised their target price on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Zacks Research upgraded shares of Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.75.

Pediatrix Medical Group Trading Up 2.3%

Shares of Pediatrix Medical Group stock traded up $0.38 during trading on Thursday, hitting $16.99. The stock had a trading volume of 753,049 shares, compared to its average volume of 757,969. The firm's fifty day simple moving average is $14.33 and its 200-day simple moving average is $14.10. The stock has a market cap of $1.48 billion, a PE ratio of 13.17 and a beta of 1.30. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. Pediatrix Medical Group, Inc. has a 12 month low of $10.06 and a 12 month high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.11. The firm had revenue of $468.84 million during the quarter, compared to analyst estimates of $464.37 million. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The business's revenue was down 7.1% on a year-over-year basis. During the same quarter last year, the business earned $0.34 EPS. As a group, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.